Should Medicare pay for the new Alzheimer’s treatment?
When the FDA approved aducanumab for early Alzheimer’s disease, they also required an additional clinical trial to generate more data on its safety and effectiveness. (See LBDA’s earlier position statement […]
Read More
NIH funds $35 million study of LBD risk factor
People with rapid eye movement (REM) sleep behavior disorder act out their dreams. While sleeping safely in bed, for example, they might throw up their arms to catch an imaginary […]
Read More
LBDA Issues Position Statement on Aducanumab
Key Highlights: The FDA approved marketing of aducanumab for the treatment of Alzheimer’s disease under a special accelerated approval process. Aducanumab has not yet been proven to slow the progression […]
Read More
LBDA Research Mentorship Program
The Lewy Body Dementia Association is interested in establishing a Research Mentorship Program. The goal of this program is to promote the continued development of newly trained clinician-researchers, or experienced […]
Read More
Statement from LBDA on Hallucination Treatment Rejected by FDA
The Lewy Body Dementia Association is deeply concerned about the recent ruling by the FDA in which it rejected ACADIA Pharmaceutical’s supplemental new drug application for pimavanserin for the treatment […]
Read More
LBD Biomarkers: Progress
LBDA’s Research Centers of Excellence (RCOE) program presented a virtual symposium on “biomarkers” on January 25, 2021. A biomarker is a biological sign that reveals the presence or severity of […]
Read More
Sitting in the “genetic cross-hairs” of Alzheimer’s and Parkinson’s
Study locates five genes that may play a critical role in Lewy body dementia. Source: National Institutes of Health In a study led by National Institutes of Health researchers, scientists […]
Read More
The Virtual Assessment in Lewy Body Dementia: Pandemic and Beyond – A Series of 3 Webinars in 2021
The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. Those with LBD represent a particularly vulnerable population to the complications of COVID-19 given advanced age […]
Read More
What’s in a Name? It Depends on Who’s Using It
What’s Alzheimer’s disease (AD)? A person off the street will probably describe a memory problem. A healthcare professional will likely say the same. In fact, AD is what happens at […]
Read More
LBDA Partners with Medscape
Despite being a common form of dementia, there is still a tremendous need for more physician education on Lewy body dementia (LBD). To address this issue, LBDA is proud to […]
Read More
Shifting into Virtual Mode for LBD Research Meetings
In February of 2020 B.C. (before COVID-19), LBDA planned to host/attend 3 day-long meetings related to LBD research in June in Cleveland, OH. And then the pandemic hit. So, we […]
Read More
New Research Definition of Mild Cognitive Impairment with Lewy bodies (MCI-LB)
Most people with Lewy body dementia (LBD) will experience mild changes in thinking; over time, these symptoms, referred to as mild cognitive impairment (MCI), worsen and may become dementia. As […]
Read More
Alzheimer’s and Lewy bodies: When Two Pathologies Collide
DLB is one of two clinical diagnoses under the Lewy body dementia umbrella. When DLB co-occurs with Alzheimer’s disease, a clinical diagnosis is even more difficult to make as symptoms […]
Read More
LBD and Coronavirus: Prevention is the Best Medicine
With all of the news about the coronavirus and the condition “COVID-19,” here are some things that LBD families should keep in mind in the coming weeks and months. This […]
Read More
Loss of Attention May Suggest Faster Progression to Dementia in Very Early LBD
Like other dementias, a person doesn’t develop Lewy body dementia (LBD) overnight. Very mild symptoms worsen over time until medical attention is needed. Sometimes several years pass before these earliest […]
Read More
Biogen’s Aducanumab Clinical Trial Results Revealed
In a stunning reversal last October, pharma giant Biogen announced that its failed Phase 3 clinical trial of aducanemab in people with mild cognitive impairment or mild Alzheimer’s disease didn’t […]
Read More
Positive Results for the HARMONY Clinical Trial of Pimavanserin in Dementia-Related Psychosis
In December ACADIA Pharmaceuticals presented its top-line results from its Phase 3 clinical trial of pimavanserin in people who had dementia-related psychosis. The results had been eagerly awaited; ACADIA stopped […]
Read More
LBDA’s Contributions to the Scientific Community
Throughout the year, LBDA staff have been traveling across the country to promote discussion and awareness of Lewy body dementias in local communities and at national conferences. Here are just a […]
Read More
LBD Caregiver Experience Differs Between Spouses and Adult Children
Being a dementia caregiver can have a negative impact on one’s psychological well-being. But what is specifically known about the impact of LBD caregiving? And how it might differ based […]
Read More
Updated LBD Research Recommendations Published
Every 3 years, a national research summit is held to update research strategies for non-Alzheimer’s dementias. This 2-day national event is one of 3 rotating summits held in response to […]
Read More